Mentioned:
Eli Lilly wants to be on the leading edge of drug discovery breakthroughs enabled by artificial intelligence. Which is exactly why they’re deepening their partnership with Nvidia.
What’s happening:
- Nvidia (NASDAQ: NVDA) and Eli Lilly (NYSE: LLY) have formed a partnership focused on using artificial intelligence for developing new drugs and therapeutics
Why it matters:
- Eli Lilly and Nvidia will invest up to $1B USD into the partnership which is primarily focused on the build out of a new innovation lab in San Fransisco, California
Going deeper:
- The new innovation lab in San Francisco will be built on Nvidia’s BioNeMo platform and their leading edge Vera Rubin architecture
- Eli Lilly and Nvidia have also both publicly stated they plan to leverage robotics to accelerate and scale the development of new novel therapeutics and breakthroughs in drug discovery
- Eli Lilly previously made waves in the pharmaceutical space when they cut a deal with Nvidia to build out their own artificial intelligence powered supercomputer to train large models for validating new molecules and running drug discovery workloads
The intrigue:
- Advanced Micro Devices (NASDAQ: AMD) has also been pursuing using large artificial intelligence models for breakthroughs in drug discovery through their partnership with MindWalk Holdings (NASDAQ: HYFT) that leverages their GPU and CPU hardware as well as their own proprietary software architecture
